<?xml version='1.0' encoding='utf-8'?>
<document id="26329454"><sentence text="Asunaprevir for hepatitis C: a safety evaluation."><entity charOffset="0-11" id="DDI-PubMed.26329454.s1.e0" text="Asunaprevir" /></sentence><sentence text="The introduction of direct-acting antiviral (DAA) agents has revolutionized the treatment of hepatitis C virus (HCV) chronic infection" /><sentence text=" Non-structural 3 protease inhibitors are currently the most numerous class of DAAs on the market" /><sentence text="" /><sentence text="This review mainly focuses on the tolerability and safety profile of asunaprevir (ASV)-containing DAA regimens"><entity charOffset="69-80" id="DDI-PubMed.26329454.s5.e0" text="asunaprevir" /></sentence><sentence text=" ASV is a second-wave protease inhibitor currently in Phase III clinical development in most countries and already available in Japan" /><sentence text="" /><sentence text="ASV shows potent antiviral effect and clinical efficacy on HCV genotypes 1 and 4" /><sentence text=" The all-oral combination daclatasvir/ASV reached high eradication rates in HCV genotype 1b and 4 infection, and a lower efficacy in genotype 1a infection"><entity charOffset="26-37" id="DDI-PubMed.26329454.s9.e0" text="daclatasvir" /></sentence><sentence text=" ASV presents a low potential for drug-drug interaction and a good tolerability as part of multiple, including all-oral, regimens" /><sentence text=" ASV is associated with a transient and usually mild increase in aminotransferase levels in a low percentage of cases" /><sentence text=" Due to the impaired pharmacokinetic profile observed in advanced liver disease, ASV use in patients with moderate or severe hepatic impairment is not allowed" /><sentence text=" In conclusion, ASV represents a powerful weapon against HCV infection and has to be considered an optimal option as a component of genotype tailored interferon-free combinations" /><sentence text="" /></document>